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ABSTRACT
Objective: In a randomised controlled trial
investigating tapering of TNF inhibitors (TNFi)
compared with usual care (UC) in rheumatoid arthritis
patients, minimal radiographic progression was more
frequent in patients who attempted tapering. Possible
explanations include higher incidence of flaring, higher
mean disease activity or lower TNFi use.
Methods: 18 months data from the DRESS study
were used. Change in Sharp-van der Heijde (ΔSvdH)
score (linear regression) and proportion of patients
with >0.5 ΔSvdH (logistic regression) were used as
outcomes. The cumulative incidence and number of
short-lived and major flares per patient, mean time-
weighted disease activity (MTW-DAS28-CRP) and TNFi
use were used as independent variables. Regression
models were performed stratified per study group and
corrected for possible confounders.
Results: 175 of 180 patients had 18-month data
available. The mean ΔSvdH were 0.75 and 0.15 units
with 37 of 116 (32%) and 9 of 59 (15%) patients
exceeding 0.5 points in the tapering and UC group,
respectively (both p<0.05). MTW-DAS28-CRP, but not
incidence or number of short-lived or major flares, or
TNFi use, was independently associated with the mean
progression score, but only in the tapering group.
Additional analyses on DAS28-CRP subcomponents
showed that this was mainly caused by MTW swollen
joint count. No confounders were identified.
Conclusions: Radiographic progression was
associated with higher MTW-DAS28-CRP (and
especially swollen joint count), but only in patients
who tapered TNFi. This finding stresses the importance
of maintaining disease activity as low as possible in
patients in whom TNFi is tapered and to check for
radiographic progression regularly.
Trial registration number: NTR 3216; Post-results.
INTRODUCTION
Disease activity-guided tapering of TNF inhi-
bitors (TNFi) in rheumatoid arthritis (RA)
results in a signiﬁcant reduction in TNFi use
and subsequent cost, without compromising
on important clinical outcomes.1 However, in
the DRESS (Dose REduction Strategy of
Subcutaneous TNF inhibitors) study, a
minimal increase in radiographic progression
was observed for patients who attempted
tapering compared with patients who contin-
ued TNFi dosing.
We propose three hypotheses that could
explain this: ﬁrst, in DRESS, short-lived ﬂares
were more frequent in patients tapering than
in patients not tapering, which is a
Key messages
What is already known about this subject?
▸ The TNF inhibitors (TNFi) tapering strategy used
in the DRESS study resulted in an increase in
radiographic progression for patients who
attempted tapering compared with patients who
continued TNFi dosing.
▸ Although this increase was minimal over
18 months, it may become significant in subse-
quent years and lead to disability.
What does this study add?
▸ We investigated possible causes and found that
higher disease activity (especially swollen joints)
in combination with lower TNF inhibitors expo-
sition was associated with the mean radiographic
progression.
How might this impact on clinical practice?
▸ This finding stresses the importance of maintain-
ing a state of low disease activity or remission in
patients in whom TNF inhibitors is tapered and to
check for radiographic progression regularly.
▸ However, further progression in subsequent years
is not to be expected, as higher disease activity is
a temporary effect of a trial-and-error tapering
strategy.
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temporary effect of the trial-and-error type of tapering
strategy. It could be hypothesised that the tapering strat-
egy leads to a higher incidence of ﬂares, thus causing
radiographic progression (in both groups or tapering
group alone).2 Second, a signiﬁcantly higher mean time-
weighted (MTW) disease activity was observed in the
tapering group, again induced by the tapering and
higher MTW disease activity could result in radiographic
progression (in both groups or tapering group alone).
Third, tapering causes lower TNFi exposition. Previous
studies have suggested that TNFi use itself may prevent
radiographic progression. Therefore, lower TNFi expos-
ition could lead to progression, independent of
increased disease activity.3–5
These hypotheses have different clinical implications.
In the ﬁrst two hypotheses, the effect is temporarily: pro-
gression is caused by a (sometimes unsuccessful) taper-
ing attempt, not by lower TNFi use itself—so in
subsequent years, damage would not progress further.
Tight control should be optimised, and if ﬂares could
be predicted, progression would be reduced. The third
hypothesis would mean an ongoing process of radio-
graphic progression in following years (ﬁgure 1), and
although the increase in progression that we found is
minimal, it may become signiﬁcant in subsequent years
with consequent loss of function or pain symptoms. It
would not be preventable by tight control alone and
would require frequent radiographic monitoring and
adaptation of TNFi use.
Therefore, we investigated the effects of the occurrence
of short-lived or major ﬂare, MTW disease activity and
TNFi exposition on radiographic progression in patients
tapering TNFi compared with patients not tapering.
PATIENTS AND METHODS
Patients and definitions
Clinical and radiographic data from the DRESS study
were used: an 18-month, open randomised clinical trial,
investigating non-inferiority of a disease activity-guided
tapering strategy of adalimumab or etanercept com-
pared with usual care (UC).1 6
Radiographs from baseline and 18 months were
scored pairwise and in chronological order using the
Sharp-van der Heijde (SvdH) score by two researchers,
blinded for clinical outcome and study group.7 The
absolute SvdH score with subcomponents and change
(Δ) in SvdH score between baseline and 18 months were
calculated. The proportion of patients with minimal pro-
gression, deﬁned as ΔSvdH>0.5 points, was calculated.
Additionally, proportions of patients exceeding the
minimal clinically important change (MCIC) (8 points
per 18 months, based on previous values of 4 points per
year)8 9 and smallest detectable change (SDC) (4.1
points)1 were calculated.
Disease activity was deﬁned using a 28 joint-based
disease activity score (DAS28) with C reactive protein
(CRP) and MTW-DAS28-CRP was calculated over
18 months. For (short-lived) ﬂare, a validated ﬂare cri-
terion was used: DAS28 increase of >1.2 compared with
baseline, or DAS28 increase of >0.6 and current DAS28
≥3.2.10 A major ﬂare was deﬁned as a ﬂare lasting
>3 months. The cumulative incidence of patients with
short-lived or major ﬂare and number of short-lived or
major ﬂares per patient were calculated.
TNFi use was calculated in the dose reduction and UC
group, as the normalised proportion of the deﬁned
daily dose (DDD) of TNFi, with 1.0 as full-dose equiva-
lent. DDD: 40 mg/14 days for adalimumab and 50 mg/
7 days for etanercept.
Statistical analyses
STATA/IC V.13.1 was used. Descriptive statistics were per-
formed, (non) parametrically when appropriate.
Univariate and multivariate analyses were performed
with cumulative incidence and number of short-lived
and major ﬂares per patient, MTW-DAS28-CRP and
TNFi use as independent variables. The radiographic
progression yes/no (ΔSvdH >0.5; logistic regression) and
mean ΔSvdH (linear regression) were used as depend-
ent variables. Possible confounders that were checked
were: age, sex, body mass index, smoking, baseline SvdH
score, DAS28-CRP, CRP, rheumatoid factor,
Figure 1 Hypotheses for causes
of progression and development
over time.
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anticitrullinated protein antibody status, oral glucocortic-
oid use and intramuscular or intra-articular glucocortic-
oid injections, number of glucocorticoid injections per
patient and synthetic disease-modifying antirheumatic
drug use. To check for effect modiﬁcation, all analyses




One hundred and seventy-ﬁve (116 taper group/59 UC)
of 180 patients had clinical and radiographic data avail-
able. Baseline characteristics were comparable between
patients with missing and non-missing data.
The mean SvdH scores were 38.3 (SD 49.3) and 42.1
(58.7) at baseline (p=0.65), and 39.0 (49.6) and 42.2
(58.7) at 18 months (p=0.71) for the taper and UC
groups, respectively (table 1). The mean ΔSvdH over
18 months were 0.75 (1.5) and 0.15 (1.1) in the taper
and UC groups, respectively (p<0.05). The difference in
ΔSvdH between groups was mainly caused by joint space
narrowing; change in erosion score was similar (table 1).
No patients exceeded the MCIC. The SDC was exceeded
by ﬁve (4%) patients in the taper group and no patients
in the UC group. Minimal progression was found in 37
of 116 (32%) and 9 of 59 (15%) patients in the taper
and UC groups, respectively (p<0.05).
Disease activity and (major) flare
MTW-DAS28-CRP was 2.3 (0.5) and 2.1 (0.6) in the
taper and UC groups, respectively (p<0.01). For patients
with minimal progression, the median MTW-DAS28-CRP
was 2.3 (IQR 2.0–2.8) in the taper group and 2.0 (1.9–
2.4) in the UC group. Additional data on the mean
DAS28-CRP at certain time points are provided in online
supplementary table S1. Short-lived ﬂares occurred in 84
of 116 (72%) in the taper group and 16 of 59 (27%) in
the UC group (p<0.001). The cumulative incidence of
major ﬂare was 14 of 116 (12%) and 6 of 59 (10%) in
the taper and UC groups, respectively.
TNFi exposition
The median proportions of DDD were 0.47 (IQR 0.27–
0.68) and 1.00 (IQR 0.95–1.00) in the taper and UC
groups, respectively (p<0.0001). The lower bound of the
IQR of the median proportion of DDD was slightly
below 1.00 in the UC arm due to patients: discontinuing
because of adverse events (n=6) or inefﬁcacy (n=2);
tapering because of low disease activity (n=5); being on
lower than DDD dose at inclusion (n=2).
Regression modelling
Logistic regression with ΔSvdH >0.5 yes/no as depend-
ent variable did not yield any association with short-
lived or major ﬂares, MTW-DAS28-CRP or TNFi use. In
univariate linear regression with the mean ΔSvdH as
dependent variable, only MTW-DAS28-CRP, not occur-
rence of short-lived or major ﬂares or TNFi use, was
independently associated with progression (β=0.51
(p=0.005)). In multivariate analyses, only
MTW-DAS28-CRP remained signiﬁcantly associated with
the mean ΔSvdH. Effect modiﬁcation was present by
allocation group (table 2), with a signiﬁcant association
between MTW-DAS28-CRP and progression in the taper
group, but not in the UC group. Stratiﬁed corrected
analyses for the taper and UC groups showed non-
signiﬁcant associations, except for MTW-DAS28-CRP.
Additional exploratory analyses on subcomponents of
DAS28-CRP showed that MTW tender and swollen joint
count (MTW-TJ and MTW-SJ) were signiﬁcantly asso-
ciated with the mean progression in the taper group.
Patient global visual analogue scale (PG-VAS) and CRP
were not signiﬁcantly associated with the mean progres-
sion (table 2). Collinearity between MTW-TJ and
MTW-DAS28-CRP was high (>0.7) but lower for
MTW-SJ and MTW-DAS28-CRP, thus, MTW-SJ was
added to the model. Afterwards, only MTW-SJ
remained signiﬁcantly associated with the mean pro-
gression in the taper group with β=0.52 (95% CI
0.05 to 0.99) (table 3). No signiﬁcant confounding was
identiﬁed.




(n=59) Difference (95% CI)
Total
(n=175)
SvdH baseline* 38.3 (49.3) 42.1 (58.7) −3.79 (−20.4 to 12.8) 39.6 (52.5)
SvdH 18 months* 39.0 (49.6) 42.2 (58.7) −3.19 (−19.9 to 13.5) 40.1 (52.7)
Progression SvdH score* 0.75 (1.5) 0.15 (1.1) 0.60 (0.16 to 1.0) 0.55 (1.4)
Progression erosion score* 0.29 (0.8) 0.12 (0.7) 0.17 (−0.07 to 0.42) 0.23 (0.8)
Progression joint space narrowing* 0.46 (1.2) 0.03 (0.9) 0.43 (0.07 to 0.78) 0.32 (1.1)
Progression >MCIC† 0 (0) 0 (0) 0 (0) 0 (0)
Progression >SDC† 5 (4) 0 (0) 5 (4) 5 (3)
Progression >0.5† 37 (32) 9 (15) 28 (17) 46 (26)
*Mean with SD.
†Number (%) of patients.
MCIC, minimal clinical important change (8 units); Progression SvdH, Sharp-van der Heijde progression between baseline and 18 months;
SDC, smallest detectable change (4.1 units); SvdH, Sharp-van der Heijde score.
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DISCUSSION
In this study, we investigated possible causes of the
minimal difference in radiographic progression in RA
patients tapering TNFi compared with UC that was
observed in the DRESS study. Analyses yielded an associ-
ation between MTW disease activity and radiographic
progression, but only in the tapering group. No associ-
ation was found between the occurrence or number of
ﬂares or lower TNFi exposition and radiographic
progression.
Additional analyses on subcomponents of DAS28-CRP
showed that radiographic progression was mainly caused
by swollen joint count. Thus, it is the small overall
increase in disease activity over time, and more speciﬁc-
ally swollen joints, caused by the tapering strategy, and
not the intermittent episodes of high disease activity
(ﬂares) that appear to cause progression. This suggests
that radiographic progression occurs when two necessary
causes (higher disease activity and tapering) are present.
Therefore, tight control—although also important in
non-tapering patients—is even more important when
tapering TNFi, to prevent additional progression.
However, further progression in subsequent years is not
to be expected, as higher disease activity is a temporary
effect of a trial-and-error tapering strategy, and disease
activity was similar between dose reduction and the UC
group at 18 months.
Our study has some limitations. First, the follow-up
time of 18 months was limited. Furthermore, the level of
radiographic progression that is of clinical relevance is
somewhat debatable. In 2006, Welsing et al8 established a
level of ﬁve Sharp-Van der Heijde points per year as the
minimal clinically important change. This level may be
different for the current RA population treated with
more strict tight control. Therefore, we also analysed
progression with different cut-off levels (SDC and
minimal progression <0.5 SvdH points), as well as with
continuous SvdH score to be as sensitive as possible.
Finally, the observed SDC is relatively high and some
misclassiﬁcation of patients with progression that is actu-
ally due to measurement error could be present.
However, this would cause bias towards a null result,
whereas we did ﬁnd differences in radiographic progres-
sion and in associations between disease activity and
progression.
Our ﬁndings are in line with three studies that have
shown some effect of discontinuation but no effect of
tapering of TNFi tapering on radiographic progression
in RA.11–13 In the STRASS study, patients were rando-
mised to disease activity-guided TNFi tapering or
Table 2 Univariate linear regression models stratified by allocation group
Tapering group Usual care group
β 95% CI β 95% CI
MTW-DAS28-CRP 0.64 0.14 to 1.14 0.17 −0.29 to 0.62
Constant −0.73 −0.20
MTW-TJ 0.24 0.07 to 0.10 0.05 −0.13 to 0.24
MTW-SJ 0.65 0.25 to 1.04 0.21 −0.19 to 0.62
MTW-PG-VAS 0.02 −0.0001 to 0.38 0.004 −0.02 to 0.03
MTW-CRP −0.001 −0.05 to 0.05 0.006 −0.03 to 0.05
Occurrence of flare 0.24 −0.38 to 0.87 0.091 −0.57–0.75
Constant 0.58 0.13
Number of flare per patient −0.025 −0.34 to 0.29 0.041 −0.36 to 0.44
Constant 0.78 0.14
Occurrence of major flare 0.69 −0.16 to 1.53 0.82 −0.86 to 1.08
Constant 0.67 0.14
Number of major flare per patient 0.71 −0.06 to 1.47 0.11 −0.86 to 1.08
Constant 0.66 0.14
TNFi use (% ddd) 0.43 −0.65 to 1.51 −0.068 −1.38 to 1.25
Constant 0.54 0.21
%ddd, percentage of the defined daily dose; CRP, C reactive protein; MTW-DAS28-CRP, mean time-weighted DAS28-CRP; PG-VAS, patient
global visual analogue scale; SJ, swollen joint count; TJ, tender joint count.
Table 3 Final linear regression model stratified by allocation group
Tapering group Usual care group
β 95% CI β 95% CI
MTW-DAS28-CRP 0.28 −0.30 to 0.87 −0.02 −0.70 to 0.65
MTW-SJ 0.52 0.05 to 0.99 0.23 −0.37 to 0.84
Constant −0.24 −1.5 to 1.01 0.07 −1.15 to 1.29
MTW-DAS28-CRP, mean time-weighted DAS28-CRP; SJ, swollen joint count.
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continuation of treatment.11 Multiple tapering attempts
were allowed. A difference in disease activity and relapse
rate was observed, but no difference in radiographic pro-
gression. Follow-up time and SDC were comparable to
our study, but sample size was smaller, which may explain
the null result. In PRESERVE, patients were treated with
etanercept and methotrexate for 36 weeks after which
they were randomised to etanercept ﬁxed dose halving,
discontinuation or full-dose continuation.12 A signiﬁcantly
greater proportion of patients in the discontinuation
group exceeded the SDC compared with patients con-
tinuing etanercept. This was explained by the fact that
patients had moderate disease activity and were refractory
to methotrexate monotherapy at study start. Furthermore,
disease activity was not steered on, leading to a signiﬁcant
rise in DAS28 after etanercept discontinuation. Finally,
Raffeiner et al13 showed that randomisation of RA patients
in remission under etanercept, to either receive ﬁxed
halve dose etanercept or continuation of full-dose etaner-
cept, did not lead to differences in radiographic progres-
sion after 2 years. However, this study did not include
discontinuation of etanercept.
In conclusion, disease activity-guided TNFi tapering
may result in a small increase in radiographic progres-
sion. This is possibly due to the disappearance of the
direct inhibitory effect of TNFi on radiographic progres-
sion (‘disconnect’), so that inﬂammation resumes
driving this progression. These ﬁndings stress the
increased importance of maintaining a state of low
disease activity or remission—especially low swollen joint
count—in patients in whom TNFi is tapered and to
check for radiographic progression regularly. Long-term
studies on TNFi tapering need to conﬁrm that radio-
graphic damage does not continue to progress over the
years. Also, future studies should focus on predictors of
successful tapering or discontinuation to further prevent
the rise in disease activity that is the consequence of
tapering.
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